Revance Therapeutics (RVNC) Tops Q4 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Revance Therapeutics (RVNC) Tops Q4 EPS by 13c

Revance Therapeutics Releases Second Quarter 2015 Results

August 6, 2015 4:02 PM EDT

NEWARK, Calif., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ: RVNC), a specialty biopharmaceutical company developing botulinum toxin products for the use in aesthetic and therapeutic indications, announced today results for the second quarter ended June 30, 2015.

Recent Pipeline Highlights

Topical RT001 Aesthetic Indication for the Treatment of Lateral Canthal (Crow's Feet) Lines Announced plans to initiate a US Phase 3 pivotal study for the treatment of crow's feet lines using investigational drug product candidate RT001, a topical gel formulation of botulinum toxin type A. Topical RT001... More